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Abstract: Cervical cancer continues to be the second largest cause of cancer deaths in women 
worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a nec-
essary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive 
strategy to prevent cervical cancer. Current strategies for the development of safe and effective 
preventive vaccines are based on the induction of neutralizing antibodies against the major capsid 
protein, L1 of HPV. Cervarix™ is one of the preventive HPV vaccines that has been approved in 
the Europe and Australia and is currently under review by the US Food and Drug Administra-
tion. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated 
in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high 
proportion of precursor lesions of cervical cancer caused by these two HPV types. This review 
explores the various features of this new vaccine candidate and discusses the future directions 
in the ﬁ  eld of HPV vaccine development.
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Introduction
Cervical cancer continues to be a major health care problem worldwide. Cervical 
cancer is the second leading cause of cancer death in women in developing countries, 
although cytological screening programs have substantially reduced its toll in devel-
oped countries (Parkin et al 1999). It is known that oncogenic human papillomaviruses 
(HPVs) are the primary causal agent of cervical cancer (Walboomers et al 1999). 
More than 99% of cervical cancers and over 90% of their precursor lesions, squamous 
intra-epithelial lesions (SIL), contain HPV DNA (Walboomers et al 1999). Although 
more than 200 genotypes of HPV have been identiﬁ  ed, a small number of genotypes 
are highly associated with cancer, especially HPV16 and HPV18 (de Villiers et al 
2004). These are termed “high-risk” types and are frequently associated with SIL 
(also called cervical intraepithelial neoplasia [CIN]), the precursor lesions of cervical 
cancer (for review see Roden and Wu (2006)).
HPVs are non-enveloped icosahedral viruses, with a circular, double-stranded 
DNA genome. The genome of this small DNA virus encodes two classes of genes; 
early and late. The early gene products regulate viral DNA replication (E1, E2), viral 
RNA transcription (E2), cytoskeleton reorganization (E4) and cell transformation 
(E5, E6, E7), whereas the late proteins (L1, L2) are structural components of the viral 
capsid. Expression of the viral proteins is tightly regulated and associated with the 
differentiation of infected epithelial cells. E2 is the master regulator that regulates 
the expression of all the other viral genes, and is particularly involved in the repres-
sion of E6 and E7. The viral oncogenes E6 and E7 are responsible for transforma-
tion. During progression, the HPV genome integrates into the host chromosomal 
DNA, leading to the disruption of the viral E2 gene and an inability to express the 
late genes associated with high grade disease. Since E2 is a transcriptional repressor Biologics: Targets & Therapy 2008:2(1) 108
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of E6 and E7, loss of E2 leads to upregulation of E6 and 
E7 genes. The elevated expression of E6 and E7 proteins 
results in the disruption of cell cycle regulation and leads to 
genomic instability, thereby contributing to the progression 
of HPV-associated cervical cancer. Notably, their expression 
is necessary to maintain the transformed phenotype (for a 
review, see zur Hausen (2002)).
A thorough knowledge of these concepts of HPV virology 
is essential for the rational development of vaccines against 
HPV. Vaccination could be implemented in the form of 
preventive vaccines, which generate neutralizing antibodies 
to block HPV viral infection or in the form of therapeutic 
vaccines, which eliminate infection by inducing a virus-
speciﬁ  c T cell-mediated response. Current strategies for the 
development of safe and effective preventive vaccines are 
based on the induction of neutralizing antibodies against 
the major and minor capsid proteins, L1 and L2 of human 
papillomavirus. The newly licensed preventive HPV vac-
cine, Gardasil® (Merck and Co, Inc.), which is an L1-based 
vaccine, has both a remarkable safety proﬁ  le and clinical 
efﬁ  cacy against the HPV genotypes from which it was 
derived. Continued efforts are being made in the ﬁ  eld of 
L1-based vaccines in order to improve their efﬁ  cacy, by 
increasing the breadth of protection and reducing the cost 
of these vaccines for wider access and effective prevention 
of HPV infections.
L1-based vaccines
The expression of recombinant L1 in mammalian (Hagensee 
et al 1993; Heino et al 1995), insect (Kirnbauer et al 1992; 
Rose et al 1994), yeast (Sasagawa et al 1995), and even bacte-
rial cells (Nardelli-Haeﬂ  iger et al 1997) was shown to gener-
ate virus-like particles (VLPs), which were morphologically 
and immunologically similar to native virions (Kirnbauer 
et al 1992; Rose et al 1994). Studies in various animal models 
showed that these L1 VLPs induced high titers of neutraliz-
ing serum antibodies, speciﬁ  cally immunoglobulin G (IgG), 
and protected against cutaneous or mucosal papillomavirus 
challenge. Furthermore, it was demonstrated that L1 VLPs 
are immunogenic and protective, and this protection is medi-
ated by L1-speciﬁ  c neutralizing antibodies (Breitburd et al 
1995; Suzich et al 1995; Christensen et al 1996; Kirnbauer 
et al 1996). Interestingly, vaccination with L1 capsomeres, 
the pentameric subunit of VLPs, is also protective (Yuan 
et al 2001), but not as immunogenic as VLPs in the absence 
of adjuvants.
Clinical trials were conducted using HPV L1 VLPs and 
vaccination with these VLPs produced using baculovirus was 
shown to be well tolerated and highly immunogenic (Evans 
et al 2001; Harro et al 2001). The HPV16 L1 VLP vaccines 
induced serum antibody titers that were about 40-fold higher 
than the level observed in natural infection even without 
an adjuvant and these antibodies were highly neutralizing 
(Evans et al 2001; Harro et al 2001). Similar results were 
observed using L1 VLPs derived from other HPV types 
(Evans et al 2001; Ault et al 2004; Brown et al 2004; Fife 
et al 2004). In 2002, a landmark clinical trial was conducted 
by Koutsky et al which showed that vaccination with 
HPV16 L1 VLPs formulated in the adjuvant alum provided 
100% protection from the natural acquisition of persistent 
HPV16 infection over an average of 17.4 months (Koutsky 
et al 2002). Importantly, all nine cases of incident HPV16-
related CIN were conﬁ  ned to the placebo group, indicating 
that vaccination protects against HPV-related disease. This 
high degree of efﬁ  cacy of L1 VLP vaccines for protection 
against persistent infection and cervical disease relating to 
the same HPV type infection has also been shown in other 
clinical studies (Harper et al 2004; Harper et al 2006; Mao 
et al 2006; Villa et al 2006a; Villa et al 2006b, Paavonen 
et al 2007). Thus, the steady progress in the ﬁ  eld of L1 VLP 
vaccines led to the development of two successful vaccine 
candidates.
Cervarix™
Cervarix™ (GlaxoSmithKline) has already been approved in 
the Europe and Australia and is currently under review by 
the US Food and Drug Administration. Cervarix is a L1 VLP 
vaccine that includes HPV types 16 and 18, the two major 
serotypes that are involved with cervical cancer. Thus, the 
vaccine has been developed to protect against infection from 
the two major cancer-causing types of HPV; HPV16 and 18, 
which together are responsible for approximately 70% of 
all cervical cancers (de Villiers 1989). It has been produced 
using insect cells infected with recombinant baculovirus 
and formulated in the proprietary adjuvant ASO4, which 
consists of alum combined with a TLR4 ligand, MPL (3-O-
desacyl-4'-monophosphoryl lipid A). The vaccine requires 
three intramuscular doses. The crucial efﬁ  cacy endpoints 
have been protection from HPV-related SIL and persistent 
HPV infection by the HPV types used to derive the vaccine. 
Results of efﬁ  cacy trials have indicated that the vaccines 
are well tolerated, highly immunogenic, and capable of 
generating high titers of neutralizing antibody to the HPV 
types 16 and 18, that are included in the vaccine, thus result-
ing in a high efﬁ  cacy against CIN2+ lesions containing HPV 
16 and HPV 18 (Harper et al 2004; Paavonen et al 2007). Biologics: Targets & Therapy 2008:2(1) 109
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In a recent report on a phase III double-blind, randomized 
controlled trial, Cervarix demonstrated an efﬁ  cacy of 90.4% 
against CIN2+ lesions containing HPV 16 and 18 (Paavonen 
et al 2007). There is also some amount of cross-protection 
with the HPV types 31 and 45, thus leading to protection 
against approximately 80% of cervical cancers (Harper 
et al 2006). In addition, these vaccines have been shown to 
be effective over a 5-year period (Harper et al 2006; Gall 
et al 2007).
Issues regarding Cervarix
Although it has been established that Cervarix has an excel-
lent safety proﬁ  le and demonstrates signiﬁ  cant protection 
against persistent infection with both HPV 16 and HPV 18 
infections, there are some concerns regarding various aspects 
of the vaccine. Many of these issues are also applicable to 
Gardasil.
Type-restricted protection
Cervarix has been developed to protect against infection 
from HPV types 16 and 18, which together cause approxi-
mately 70% of all cervical cancers. Furthermore, HPV16 and 
HPV31, and HPV18 and HPV45 have very closely related 
genotypes (for review see Roden and Wu 2006; Roden et al 
2007), suggesting that vaccination with Cervarix may provide 
cross-protection against HPV types 31 and 45. Indeed, vac-
cination with Cervarix has been shown to generate partial 
cross-protection against HPV types 31 and 45 (Harper et al 
2006). However, the overall protection against cervical 
cancer provided by Cervarix is probably only up to 80% 
since this vaccine provides little or no protection against 
other high-risk HPV types, such as HPV33, HPV52 and 
HPV58 (Harper et al 2006). Furthermore, cross-protection 
may not last as long as protection against the type included 
in the vaccine.
An important approach to resolve the issue of type-
restricted protection is the employment of multivalent vac-
cines, which has been implemented in a number of licensed 
vaccines against other pathogens. However, this raises the 
cost and complexity of manufacture with progressively 
decreasing returns. The implementation of multivalent VLP 
vaccines will require that there is no interference with the 
responses compared to vaccination with individual types. It 
has been suggested that a vaccine comprising the eight most 
prevalent HPV types detected in cancer might be required 
for 90% protection against cervical cancer, assuming 
complete type-speciﬁ  city of protection (Munoz et al 2004). 
However, given partial cross-protection, this number is 
probably an over-estimate. The oncogenic HPV types that 
are present in different parts of the world are relatively 
consistent, which suggests that such a multivalent vaccine 
would be useful worldwide (Clifford et al 2005). Merck is 
currently testing an octavalent HPV VLP vaccine targeting 
6 oncogenic HPV types and is likely to at least partially 
cover several related HPV types.
An alternative approach to highly multivalent vac-
cine preparations for broad protection is the employment 
of a conserved and cross-protective antigen, such as L2. 
Vaccination with the minor capsid protein L2 has been shown 
to induce broadly cross-neutralizing antibodies in animal 
models and has shown promise in this regard (Roden et al 
2000; Embers et al 2002; Gambhira et al 2007). Therefore, 
efforts to improve the immunogenicity of L2 and develop-
ment for clinical testing of L2 vaccines are underway. The 
ability to produce L2 in Escherichia coli and the potential to 
use a single antigen suggest that L2 vaccines have potential 
as a low cost alternative or complement to the L1 VLP vac-
cines. Clinical trials are currently being planned to evaluate 
the safety of HPV L2 polypeptide vaccination in healthy 
women.
Length of protection
Although the duration of protection generated by Cervarix is 
not clear at this point, recently available data has indicated 
that Cervarix is highly efﬁ  cacious against HPV-16/18 up to 
5.5 years and prevents most CIN2+ lesions, and also shows 
continued cross-protection against HPV-45 and HPV-31 
incident infections (Gall et al 2007). Similar data are avail-
able for Gardasil. It will be important to continue to follow 
the same group of patients over time in order to acquire a 
comprehensive picture of the length of protection.
Age of vaccination
In a recent phase III trial using Cervarix in healthy volun-
teers of different age groups, higher antibody levels were 
observed in the pre-teen/adolescent group compared to those 
observed in women 15–25 years old (Pedersen et al 2007). 
This indicates that the elevated levels demonstrated in this 
younger age range may result in longer duration of protection. 
Similarly, another study using the quadrivalent HPV L1 VLP 
vaccine demonstrated robust anti-HPV neutralizing antibody 
responses that were signiﬁ  cantly higher in 10- to 15-year-
old girls and boys compared to 16- to 23-year-old females 
(Block et al 2006). For optimal effect, it is critical to vacci-
nate adolescents against infection with cancer-causing HPV 
types 16/18 well before the initiation of sexual activity with a Biologics: Targets & Therapy 2008:2(1) 110
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vaccine of sustained efﬁ  cacy. The current recommended age 
group of vaccination for Cervarix is 10–25 years.
Limitations in low resource areas
An important limitation of Cervarix is its high cost 
compared to other vaccines, which is also true in case of 
Gardasil. Since cervical cancer has a high prevalence in 
developing countries, vaccines need to be made available 
in low-resource areas in order to impact the incidence 
of cervical cancer worldwide. Cervarix is expected to 
cost about US$100 per dose and Gardasil costs US$120 
per dose in the US. Both these vaccines require three 
doses to complete the vaccination regimen. Thus, these 
vaccines may not be ideal for low-resource areas and in 
developing countries. Dramatically tiered pricing would 
be necessary for their implementation. Furthermore, these 
vaccines require refrigeration for storage, which might be 
problematic in remote and low-resource areas. Thus, in 
low-resource settings, the relative beneﬁ  ts of these vaccines 
may be restricted by poor coverage. In order to generate 
impact on the incidence of cervical cancer, it is therefore 
necessary to develop cost-effective, stable and effective 
preventive vaccines that are capable of inducing broader 
protection against most HPV types and which are suitable 
for low-resource areas.
Although current L1 VLP vaccines, Cervarix and Gar-
dasil are produced in insect cells and yeast respectively, 
higher levels of production of the vaccine in E. coli may 
be a cheaper alternative. The expression of L1 in E. coli 
produces high levels of capsomers (Li et al 1997; Rose 
et al 1998; Chen et al 2000) and vaccination with such 
capsomers induces neutralizing antibodies (Rose et al 1998; 
Fligge et al 2001) and protects dogs from experimental 
canine oral papillomavirus challenge (Yuan et al 2001). 
In addition, the L1 capsomere vaccine is likely stable at 
ambient temperatures. However, its immunogenicity rela-
tive to VLPs is unclear. Clinical trials are currently being 
planned to evaluate the safety and immunogenicity of L1 
capsomere vaccines formulated in alum. Alternatively, the 
inclusion of L1 in other vaccines, such as typhoid, tubercu-
losis or measles vaccines might represent a cost-effective 
and practical alternative that could also provide immunity 
to HPV (Reuter et al 2002; Baud et al 2004a,b; Govan et al 
2006). In addition, the use of live vectors for the delivery 
of L1 VLPs is attractive in remote and low-resource areas 
as immunity could be spread, but safety remains an issue 
with such vectors. Thus, further steps need to be taken in 
order to improve the cost effectiveness of HPV vaccines 
for successful implementation in low resource areas where 
they are most needed.
The requirement for needles and current three-dose regi-
men for the current VLP vaccines also presents a formidable 
obstacle to the delivery of these vaccines in low-resource 
areas. Many possible needle-free alternatives, including 
nasal inhalation and transdermal vaccination are being 
considered as feasible options (Nardelli-Haefliger et al 
2005; Rechtsteiner et al 2005). The regimen also presents 
a problem in low-resource areas where regular follow-up is 
highly unlikely. Thus, it is important to develop a vaccine 
formulation that does not require three doses to generate 
protective humoral immunity.
Lack of therapeutic beneﬁ  t
An important obstacle to the rapid elimination of cervical 
cancer is the current prevalence of established HPV infec-
tions and HPV-associated disease. The existing HPV L1 VLP 
vaccines, Gardasil and Cervarix do not generate therapeutic 
effect against pre-existing HPV infection. Since infected 
basal epithelial cells and cervical cancers cells do not express 
detectable levels of capsid antigen (L1 and/or L2), preven-
tive HPV vaccines targeting L1 and/or L2 are unlikely to be 
effective in the elimination of pre-existing infection and HPV-
related disease. This is a serious concern since there is cur-
rently a considerable burden of HPV infections worldwide. It 
is estimated that it would take approximately 20 years from 
the implementation of mass vaccination for highly effective 
preventive vaccines to impact the cervical cancer rates due 
to the prevalence of a signiﬁ  cant population with existing 
HPV infections and slow process of carcinogenesis. Thus, 
in order to accelerate the control of cervical cancer and treat 
currently infected patients, it remains important to develop 
therapeutic vaccines against HPV in addition to improving 
the efﬁ  cacy of preventive vaccines such as Cervarix.
Comparisons between Cervarix 
and Gardasil
Cervarix serves as an important competitive product relative 
to the recently licensed L1-based preventive HPV vaccine, 
Gardasil (FDA 2006a, b). Table 1 discusses the various 
aspects of comparison between the two vaccines. Gardasil 
is a quadrivalent vaccine that includes HPV types 6, 11, 
16 and 18. The types 16 and 18 are major high-risk HPV 
types, while the types 6 and 11 are the low-risk HPV types 
that are associated with a majority of benign genital warts 
and laryngeal papillomas. In comparison, Cervarix includes 
only the two most important high-risk types, HPV 16 and 18. Biologics: Targets & Therapy 2008:2(1) 111
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Thus, Gardasil can be used to prevent not only a majority 
of cervical cancers, but also genital warts, one of the most 
common sexually transmitted diseases.
The inclusion of HPV6 and 11 VLPs has been used to help 
justify vaccination of men, who do not get cervical cancer. Men 
suffer from HPV-related cancer (including anal, penile, head, 
and neck cancers) at a lower frequency than women because 
of the predominance of cervical cancer. This suggests that that 
cost/beneﬁ  t ratio is questionable for men since efﬁ  cacy in men has 
not yet been demonstrated. The argument that men should be vac-
cinated to provide herd immunity is also not so strong because the 
vaccine is so effective in women, suggesting that ensuring broad 
protection in women would be more cost-effective. However, if 
only women are vaccinated, then there would be little impact on 
HPV prevalence in men who have sex with men. Anal cancer is 
a signiﬁ  cant problem, particularly for this population.
Furthermore, Gardasil is produced in recombinant yeast, 
whereas Cervarix is produced using insect cells, but this does 
not seem to affect the immunogenicity of the VLPs. One can 
imagine that individuals that are allergic to yeast can turn to 
Cervarix as an alternative option and vice versa.
Another difference between Cervarix and Gardasil is 
the adjuvant used in the formulation of the ﬁ  nal product. 
Gardasil uses Merck’s alum-based adjuvant. In contrast, 
Cervarix uses the proprietary adjuvant developed by GSK, 
ASO4. The formulation of Cervarix with the ASO4 adju-
vant has been shown in clinical trials to induce a stronger 
antibody response against HPV types 16 and 18 compared 
to the same vaccine formulated with aluminium salt alone 
(Giannini et al 2006). However, head-to-head trials with 
Gardasil would be needed to conﬁ  rm this observation. In 
addition, a higher frequency of HPV L1-speciﬁ  c B cells 
was observed in individuals immunized with this bivalent 
L1 vaccine formulated with ASO4 adjuvant compared to 
the same vaccine formulated with alum. While the anti-
body responses generated by Cervarix vaccine may be 
higher than that generated by Gardasil, it is not clear if the 
observed enhanced humoral immune response translates 
into a stronger efﬁ  cacy or longer duration of protection 
compared to Gardasil. It would be important to determine 
if the employment of different adjuvants will inﬂ  uence the 
duration of protection of the two vaccines.
Conclusions
Cervarix, represents yet another success in the develop-
ment of preventive HPV vaccines. Similar to Gardasil, 
Cervarix also has an excellent safety proﬁ  le and high clini-
cal efﬁ  cacy, possibly protecting against up to 75%–80% 
of all cervical cancers if the vaccine is fully implemented. 
Although Cervarix has many similarities to Gardasil, there 
are also several unique factors that are highlighted, such 
as the adjuvant formulation, the production system and 
the HPV types included. The inclusion of the proprietary 
ASO4 adjuvant in Cervarix has led to a stronger immune 
response in vaccinated individuals, although it is not clear 
if this will lead to greater efﬁ  cacy or longer duration of 
protection. However, Cervarix, like Gardasil is mainly 
available in developed countries. Thus, these vaccines are 
unlikely to reach the people in the low-resource areas, who 
need them the most. Since more than 80% of all cervical 
cancer deaths occur in developing countries that lack the 
resources and infrastructure for cytologic screening and 
intervention, it is essential to make signiﬁ  cant efforts to 
develop cost-effective vaccines that are stable and can be 
administered in a simple regimen (heat-stable, needle-free, 
single vaccination) and thus can be effectively employed 
Table 1 Comparisons between Cervarix and Gardasil
Category Cervarix Gardasil
HPV types Included HPV 16 and 18 HPV 16, 18, 6, 11
Production system Insect cells infected 
with recombinant 
baculovirus
Yeast
Adjuvant ASO4 (aluminium salt 
+ MPL (3-O-desacyl-
4'-monophosphoryl 
lipid A))
Alum
Diseases covered Anogenital cancers, 
including cervical, 
vulval, vaginal, and 
anal cancers and their 
associated precursor 
lesions (and a subset 
of head and neck 
cancers)
Anogenital cancers, 
including cervical, 
vulval, vaginal, and 
anal cancers and their 
associated precursor 
lesions (and a subset of 
head and neck cancers) 
Genital warts and 
laryngeal papillomas
Available data regard-
ing Length of protec-
tion
5.5 years At least 5 years
Dose 0.5 mL dose containing 
20 μg HPV 16 L1 and 
20 μg HPV18 L1
0.5 mL dose contain-
ing 20 μg HPV6 L1, 
40 μg HPV 11 L1, 
40 μg HPV16 L1 and 
20 μg HPV18 L1
Recommended admin-
istration Route and 
regimen
Three intramuscular 
injections at 0, 1, and 
6 months
Three intramuscular 
injections at 0, 2, and 
6 months
Recommended age 
group for vaccination
10–25 9–26
Price (US$) Approx. $100 per dose Approx. $120 per doseBiologics: Targets & Therapy 2008:2(1) 112
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in low-resource areas in order to maximize the impact of 
vaccination on the global cervical cancer burden. Finally, 
since HPV also contributes to a large proportion of other 
cancers, including head and neck, vaginal, vulvar, anal, 
and penile cancers, it will be of interest to determine if 
these HPV vaccines are effective in protecting against 
these cancers as well.
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